Moreover, FLT3, TP53, and NRAS mutations are classified as driver oncogenes in AML, and co-occurring mutations in those genes have been associated not only with resistance but also with metabolic adaptations [28,35,36,37]. The gene discussed is NRAS; the disease is acute myeloid leukemia.